Market access

Results: 1 - 7 of 7
view
To what extent can the European Society for Blood and Marrow Transplantation (EBMT) registry enable outcomes-based reimbursement in oncology in the UK?

In previous work, we have shown that outcomes-based reimbursement (OBR), whereby payments to...

Read more
view
To what extent can the Systemic Anti-Cancer Therapy (SACT) database enable outcomes-based reimbursement in oncology in England?

In previous work, we have shown that outcomes-based reimbursement (OBR), whereby payments to...

Read more
view
Quantifying the cost of implementing an outcomes-based managed entry agreement in acute lymphoblastic leukaemia (ALL)

Outcomes-based managed entry agreements (MEAs) can enable patient access to promising high cost...

Read more
view
Identifying the price and access potential of a novel ATMP in the United States

The HE&MA function of the CGT Catapult engaged with an ATMP developer to identify the US...

Read more
view
Enabling a valuable engagement with EMA and HTA bodies as part of the Parallel Consultation procedure

A key challenge for the commercial viability of ATMPs is achieving both a high price and...

Read more
view
Health economics and market access

Understanding how price, revenue and profit margins can be maximised is key to any commercial...

Read more
view
Creating EU market access roadmaps for cell and gene therapies

In response to the lack of sufficient information on market access processes for cell and gene...

Read more

Discover who we are

 
Sign up